R. Jostock

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease

A. Maelicke, M. Samochocki, R. Jostock, 2001, Biological Psychiatry.

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Martin Radina, Marion Zerlin, A. Maelicke, 2003, Journal of Pharmacology and Experimental Therapeutics.

The cAMP Pathway Sensitizes VR1 Expressed in Oocytes from Xenopus laevis and in CHO Cells

R. Jostock, J. Rupp, H. Nawrath, 2003, Pharmacology.

Cell fate specification in an in vitro model of neural development.

M. Rentrop, A. Maelicke, R. Jostock, 1998, European journal of cell biology.

Nociceptin/orphanin FQ opioid peptide‐receptor expression in pachyonychia congenita

R. Jostock, M. Polydefkis, W. Schröder, 2018, Journal of the peripheral nervous system : JPNS.

Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1

K. Schiene, V. Erdmann, R. Jostock, 2007, Neurochemistry International.

Characterization of the mouse cold‐menthol receptor TRPM8 and vanilloid receptor type‐1 VR1 using a fluorometric imaging plate reader (FLIPR) assay

R. Jostock, T. Germann, H. Hatt, 2004, British journal of pharmacology.

Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR

A. Maelicke, M. Samochocki, R. Jostock, 2000, Acta neurologica Scandinavica. Supplementum.